AVTX Avalo Therapeutics Inc

$AVTX For anyone wondering why this is dropping $ABBV s competitor just released positive phase 3 results on HS.

$AVTX holy… wish I would’ve had some money left, I definitely would’ve bought me a good amount here. This stock dumped way too much, wouldn’t be surprised if it reached $12 soon.

$AVTX the October $10/$30 spreads likely got added to again as well today. Another $3M in those. See if OI confirms tomorrow.

$AVTX Avalo Therapeutics: Buy Rating Reiterated as Abdakibart's Differentiated Profile and Upcoming Milestones Support Unchanged $30 Price Target.

$AVTX $ABBV : AVTX has stronger reported efficacy: Its 42%–43% HiSCR75 response compares favorably with AbbVie’s 31%. Great buy on the dip! 💪 👀

$AVTX 🤣🤣🤣🤡🤡🤡🤡. Neil's going to take all of you peoples money. How much down from highs??? Crooks, shit all over the Aevi CVR shareholders. Crooks. NFA JMO. 🖕

$AVTX: Avalo Therapeutics will present additional Phase 2 LOTUS data for abdakibart in hidradenitis suppurativa at the EADV 2026 Congress, including a late-breaker oral presentation on October 1. The company plans to advance abdakibart into a registrational Phase 3 program in the first half of 2027. Avalo also reported $472.2M in cash, cash equivalents and investments as of June 30, with management saying its current resources are expected to fund operations into 2029.

$AVTX i always been a MITX long, AbbVie failed because IL-1 Alfa has shown to be irrelevant to the cause of HS. This could be a easy double from here. Starting a small speculative position

$AVTX Watching this week for an entry around $5 - $5.50!! No debt, fully funded for phase 3 with over $470M cash, impressive ph2 results! abdakibart still has an opportunity to prove in phase 3 over AbbVie's lutikizumab!

📉 $AVTX Top Loser #1 Move: down 37.1% 🔴 Financial Health: Weak • 0/100 🔴 Cash Flow Strength: Weak • Free cash flow -$51.46M 🔴 Profitability: Weak • Net margin -132642.4% 🟡 Valuation: Not Meaningful • P/E is not meaningful because earnings are negative; P/S is 4125.96 Analysis: Avalo Therapeutics, Inc. shows a weak financial profile. Not financial advice.

$AVTX what is a minus 40% week vs a mothers love? totally crushed, probably going to that 3.39

$AVTX under the only cash Book/sh 8.48 Cash/sh 7.46 A nice take over and we are all happy .. Maroons

$AVTX It boils down to one thing: AbbVie’s anti‑IL‑1β drug lutikizumab hit primary and multiple secondary endpoints at Week 16 in its Phase 3 trial for hidradenitis suppurativa (HS). Avalo’s entire value rests on its single asset, abdakibart — same mechanism, same indication. Avalo filed nothing with EDGAR on Oct 22; its most recent Form 4 was dated Oct 2. This is a competitive re‑rating, not company‑specific trouble.

$AVTX • Shares Sold Short: 11,405,304 shares (down -11.76% from the previous report) • Short % of Float: ~22.26% – 28.43% (considered a high short interest level) • Short % of Shares Outstanding: ~21.27% • Days to Cover (Short Ratio): ~8.8 to 9.77 days (based on recent average trading volume around 1.02 million shares) • Dollar Volume Sold Short: ~$174.84 million

$AVTX R/R on ABBV luti ph3 is just 10% down and 50-100% upside... options have taken position.